Entasis Therapeutics Holdings Inc.
ETTXDelisted Jul 11, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724344
Entasis Therapeutics Holdings Inc. was delisted on Jul 11, 2022; its insiders filed their last Form 4 on Jul 13, 2022; 27 institutions reported holding it in 13F filings for Q2 2022, worth $12.5M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Entasis Therapeutics Holdings Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Entasis Therapeutics Holdings Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Innoviva, Inc. | 10% Owner | 29,270,476Indirect | Jul 13, 2022 | 0 |
| Innoviva Strategic Opportunities LLC | Other: Former 10% Owner | 29,270,476Indirect | Jul 13, 2022 | 0 |
| Hastings David C | Director | 0 | Jul 11, 2022 | 0 |
| Meek David D. | Director | 0 | Jul 11, 2022 | 0 |
| Keiley Elizabeth M | General Counsel | 0 | Jul 11, 2022 | 0 |
| Mayer Howard | Director | 0 | Jul 11, 2022 | 0 |
| Tommasi Ruben | Chief Scientific Officer | 0 | Jul 11, 2022 | 0 |
| Perros Manoussos | President and CEO | 0 | Jul 11, 2022 | 0 |
| Behanna Heather | Director | 0 | Jul 11, 2022 | 0 |
| Mueller John Patrick | Chief Development Officer | 0 | Jul 11, 2022 | 0 |
| Altarac David | Chief Medical Officer | 0 | Jul 11, 2022 | 0 |
| Ronsheim Matthew | Chief of Pharma Sciences & MFG | 0 | Jul 11, 2022 | 0 |
| Triola Anna Diaz | Chief Commercial Officer | 0 | Jul 11, 2022 | 0 |
| Wagner Kristie Ann | VP, Principal Fin & Acct Off | 0 | Jul 11, 2022 | 0 |
| Gutch Michael | See Remarks | 167,572 | Feb 15, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Ronsheim MatthewSee Remarks | SSale | −3.76K | $3.19 | −$12.0K | −7.5%46.2K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Altarac DavidChief Medical Officer | SSale | −3.76K | $3.19 | −$12.0K | −7.5%46.2K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Keiley Elizabeth MGeneral Counsel | SSale | −3.76K | $3.19 | −$12.0K | −7.5%46.2K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Tommasi RubenChief Scientific Officer | SSale | −3.76K | $3.19 | −$12.0K | −5.2%68.3K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Gutch MichaelSee Remarks | SSale | −3.76K | $3.19 | −$12.0K | −7.5%46.2K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Mueller John PatrickChief Development Officer | SSale | −4.00K | $3.19 | −$12.8K | −8.0%46.0K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Perros ManoussosSee Remarks | SSale | −12.0K | $3.19 | −$38.2K | −7.5%147.5K after | |
| Jul 13, 2022 (view filing)9:27 PM ET | Jul 8-11 | 5 daysLate | Innoviva, Inc. and 1 other10% Owner | PPurchase | +19.3M | $2.20 | +$42.4M | +192.7%29.3M after | 2 lots |